Glovadalen (developmental code name UCB-0022) is a dopamine D1 receptor positive allosteric modulator which is under development for the treatment of Parkinson's disease. It has been found to potentiate the capacity of dopamine to activate the D1 receptor by 10-fold in vitro with no actions on other dopamine receptors. As of May 2024, glovadalen is in phase 2 clinical trials for this indication. The drug is under development by UCB Biopharma. It is described as an orally active, centrally penetrant small molecule.
See also List of investigational Parkinson's disease drugs DETQ Mevidalen ASP-4345 PF-06412562 (CVL-562) Razpipadon (CVL-871) Tavapadon (CVL-751)
References